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Abstract
Purpose A number of 111In- and 99mTc-folate-based tracers
have been evaluated as diagnostic agents for imaging folate
receptor (FR)-positive tumours. A 68Ga-folate-based radio-
pharmaceutical would be of great interest, combining the
advantages of PET technology and the availability of 68Ga
from a generator. The aim of the study was to develop a
new 68Ga-folate-based PET radiotracer.
Methods Two new DOTA-folate conjugates, named P3026
and P1254, were synthesized using the 1,2-diaminoethane and
3-{2-[2-(3-amino-propoxy)-ethoxy]-ethoxy}-propylamine
as a spacer, respectively. Both conjugates were labelled with
67/68Ga. Binding affinity, internalization and externalization
studies were performed using the FR-positive KB cell line.
Biodistribution and PET/CT imaging studies were performed
in nude mice, on a folate-deficient diet, bearing KB and
HT1080 (FR-negative) tumours, concurrently. The new radio-
tracers were evaluated comparatively to the reference
molecule 111In-DTPA-folate (111In-P3139).
Results The Kd values of
67/68Ga-P3026 (4.65±0.82 nM)
and 67/68Ga-P1254 (4.27±0.42 nM) showed high affinity
for the FR. The internalization rate followed the order 67/
68Ga-P3026>67/68Ga-P1254>111In-P3139, while almost
double cellular retention was found for 67/68Ga-P3026 and
67/68Ga-P1254, compared to 111In-P3139. The biodistribu-
tion data of 67/68Ga-DOTA-folates showed high and
receptor-mediated uptake on the FR-positive tumours
and kidneys, with no significant differences compared to
111In-P3139. PET/CT images, performed with 68Ga-P3026,
showed high uptake in the kidneys and clear visualization
of the FR-positive tumours.
Conclusion The DOTA-folate conjugates can be efficiently
labelled with 68Ga in labelling yields and specific activities
which allow clinical application. The characteristics of the
67/68Ga-DOTA-folates are comparable to 111In-DTPA-fo-
late, which has already been used in clinical trials, showing
that the new conjugates are promising candidates as PET
radiotracers for FR-positive tumours.
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Introduction
Folates are important vitamins for cell division and replication,
since they are involved as coenzymes in the synthesis of a
number of amino acids as well as nucleic acids. Cellular folate
transport can be mediated by the folate receptor (FR), a
membrane-anchored protein which binds physiologic folates
with high affinity in the low nanomolar level [1]. FRs are only
scarcely expressed in most normal tissues, while elevated
expression has frequently been observed in a wide variety of
human cancers (e.g. breast, cervical, colorectal, renal and
nasopharyngeal), including>90% of ovarian and endometrial
carcinomas [2–5]. Thus, FR has been used as a target for
selective delivery of drugs to these tumours, such as
radiopharmaceuticals, MRI contrast agents, chemotherapeutic
agents, antisense oligonucleotides, protein toxins and
liposomes with entrapped drugs [6–9]. Once folate conjugates
are bound to FR they are transported into the cell through
receptor-mediated endocytosis [10, 11].
Most of the folate-based radiopharmaceuticals have been
developed for single photon emission computed tomography
(SPECT) imaging, labelled with 99mTc [12–18] or 111In
[19–21]. Among these radioconjugates 111In-diethylenetriami-
nepentaacetic acid (DTPA)-folate, developed by Green et al.
and Low et al., has been evaluated in patients suffering from
ovarian cancer in a phase I/II study [22]. 111In-DTPA-folate
exhibited rapid target tissue uptake and non-target tissue
clearance, which gives the possibility of image acquisition at
early time points after injection, while differentiation between
benign and malignant masses was possible in patients with
suspected new disease. Despite the encouraging results of the
study more attention was paid to the development of 99mTc-
labelled folate conjugates mainly because of the short half-life
of 99mTc (T1/2=6 h), its availability (generator produced) and
cost-effectiveness, parameters important for routine clinical
application. A folate derivative coupled with a hydrophobic
N3S chelator for
99mTc labelling, named 99mTc-EC20,
developed by Leamon et al. and Reddy et al. [14, 15], has
recently been used in a pilot study in patients with various
solid tumours [23].
Nowadays positron emission tomography (PET) is becoming
a dominating method in molecular imaging, since it combines
the potential to quantify the tracer uptake within lesions with a
relatively high resolution and a remarkably high sensitivity of up
to 10−12 M. In combination with computed tomography (CT),
providing anatomical information, hybrid instruments were
developed that make the new technique PET/CT even more
powerful. Among the β+ emitters used for PET imaging, 68Ga
[T1/2=67.71 min, Ebþ = 740 keV (89%)] deserves special
attention. Its availability from long-lived 68Ge/68Ga generators,
cost-effectiveness, rendering 68Ga radiopharmacy possible in
each hospital, well-established coordination chemistry of Ga3+
that allows developing agents resistant to in vivo transchelation
of 68Ga3+ and its suitable imaging properties make it attractive
for clinical application [24, 25].
Folate conjugates for gallium complexation have been
studied by the groups of Low and Green using deferoxamine
(DF) as a chelator, since DF is known to form stable complexes
with Ga3+ [26–29]. Studies were performed with 67Ga for
SPECT imaging [26–28] and more recently with 66Ga for
PET imaging [29]. The 66/67/68Ga-DF-folate conjugates
showed good pharmacokinetics but also exhibited partial
hepatobiliary clearance which is considered a limitation in
cases of accurately imaging abdominal regions in humans,
such as ovarian carcinoma. In order to overcome this obstacle
the same group replaced DF with DTPA, which is ideal for
labelling with 111In [19, 20], but not with 67/68Ga. Indeed,
111In-DTPA-folate showed a promising in vivo profile in
animals, which led to clinical trials. This indicates the need for
the development of new folate conjugates capable of being
labelled with a variety of radionuclides, including 67/68Ga.
We have developed and evaluated two new 68Ga-folate-
based radiotracers. The chelator 1,4,7,10-tetraazacyclodode-
cane-1,4,7,10-tetraacetic acid (DOTA), which is known to
form stable complexes with Ga3+, was attached to the folate
moiety using two different spacers. The two new conjugates
were labelled with 67/68Ga and preclinically evaluated in vitro
and in vivo. For this purpose the KB cells (human
nasopharyngeal carcinoma cell line) overexpressing the FR,
which are most often used for the evaluation of FR-targeting
agents, were used along with the HT1080 cells (human
fibrosarcoma cell line), which were used as a negative control
[30, 31]. Additionally, we compared our molecules with the
“gold standard” folate-based SPECT radiotracer 111In-DTPA-
folate, which was synthesized and evaluated in parallel in all
the assays and experiments of this study.
Materials and methods
General
All chemicals were obtained from commercial sources and
used without further purification. 67GaCl3 and
111InCl3 were
purchased from Mallinckrodt-Tyco (Petten, The Netherlands).
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The 68Ge/68Ga generator was obtained from Cyclotron Co.
Ltd. (Obninsk, Russia). Analytical reverse-phase high-
performance liquid chromatography (RP-HPLC) was per-
formed on a Hewlett Packard 1050 HPLC system (Waldbronn,
Germany) with amulti-wavelength detector and a flow-through
Berthold LB 506 C1 gamma detector using aWaters Symmetry
C18 column (4.6×250mm). The gradient system consisted of a
mixture of water with 0.1% trifluoroacetic acid (TFA) (solvent
A) and acetonitrile (solvent B), using the following gradient:
0–20min, 95–80%A; 25min, 80%A; 30min, 50%A; 32min,
95% A; 35 min, 95% A; at a flow rate of 0.75 ml/min.
Electrospray ionization mass spectroscopy (ESI-MS) was
performed on a Waters ZMD (Micromass) with an HP 1100
Quaternary LC pump. Quantitative gamma counting was
performed on a COBRA 5003 gamma system well counter
from Packard Instruments (Geneva, Switzerland). All reagents
used in cell cultures were purchased from BioConcept
(Allschwil, Switzerland).
Synthesis of the folate conjugates
The molecular formulas of the folate conjugates are shown
in Fig. 1. The conjugates were synthesized in seven steps,
using slightly modified published protocols [21]. A
schematic representation of the synthetic route of P3026 is
presented in Fig. 2.
Briefly, (a) a solution of di-tert-butyl (tBu) dicarbonate
in dichloromethane (DCM) was added dropwise to 1,2-
diaminoethane in a ratio of 1:4 and allowed to react for 2 h
at room temperature (RT), followed by extraction with
water. The organic layer was dried over Na2SO4 and the
product was purified by flash chromatography. (b)
9-Fluorenylmethoxycarbonyl (Fmoc)-Glu-OtBu was
coupled to (2-amino-ethyl)-carbamic acid tert-butyl ester
(1) after activation with N-hydroxysuccinimide (NHS) using
dicyclohexylcarbodiimine (DCC) as a coupling reagent. The
reaction took place in DCM for 2 h at RT, followed by
the same procedure described above for the isolation of the
product. (c) The Fmoc group was removed with 20%
piperidine in acetonitrile, under argon atmosphere, and the
reaction mixture was evaporated and purified by flash
chromatography. (d) Coupling of pteroic acid to 2-amino-4-
(2-tert-butoxycarbonylamino-ethylcarbamoyl)-butyric acid
tert-butyl ester (3) was performed in a ratio of 1:1 in dimethyl
sulfoxide (DMSO) under argon atmosphere using 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDCI) as an activating
reagent and hydroxybenzotriazole (HOBt) as a coupling
reagent. The reaction mixture was incubated at 40°C
overnight followed by precipitation in water. The residue
was filtered and washed with water followed by diethyl ether.
(e) The protecting groups were removed after treatment with
TFA for 1 h at RT, followed by precipitation in diethyl ether.
(f) The prochelator DOTA(tBu)3 was dissolved in DCM and
pre-activated for 30 min with NHS and DCC under argon
atmosphere, followed by filtration of dicyclohexylurea. The
solution of the activated ester was added to 4-(2-amino-
ethylcarbamoyl)-2-{4-[(2-amino-4-oxo-3,4-dihydro-pteridin-
6-ylmethyl)-amino]-benzoylamino}-butyric acid (5) (1:1.1
ratio) dissolved in DMSO along with 2 eq of triethylamine.
After incubation for 1 h at RT the reaction mixture was
precipitated in diethyl ether. The product obtained (6) was
purified by flash chromatography. (g) The protecting groups
were removed after treatment with TFA for 6 h at RT,
followed by evaporation and precipitation in diethyl ether. The
final product (7) was purified by preparative HPLC and
identified by ESI-MS.
P1254 was obtained following the same synthetic route
using 3-{2-[2-(3-amino-propoxy)-ethoxy]-ethoxy}-propyl-
amine instead of 1,2-diaminoethane in the first step.
P3139 was obtained by using the bisanhydride DTPA as
described in the literature [19]. All conjugates were
lyophilized after purification and characterized by HPLC
and ESI-MS.
Preparation of the radiotracers
67Ga-P3026, 67Ga-P1254 and 111In-P3139 were prepared
by incubating 10 μg of each conjugate in 250 μl sodium
acetate buffer 0.4 M, pH 5.0 with 37–74 MBq 67GaCl3 or
111InCl3 at 95°C for 30 min.
natGa(NO3)3×9H2O was used
for the formation of the metal complexes natGa-P3026 and
natGa-P1254, following the same protocol.
For the preparation of 68Ga-P3026/P1254 a modified
protocol of Zhernosekov et al. was followed [32]. Briefly,
the 68Ge/68Ga generator was eluted with 7 ml HCl 0.1 N
and the eluate was loaded onto a cation exchange column
(strata-X-C, Phenomenex, Torrance, CA, USA). 68Ga was
eluted with 400 μl of a mixture of 97.6% acetone and
0.05 M HCl directly in a vial containing 400 μl 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
0.25 M. The pH was controlled and adjusted in the range
of 3.6–3.9, with HCl 0.1 M. Ten microlitres of P3026 or
P1254 solution (2 mg/ml in H2O) was then added and the
reaction mixture was incubated at 95°C for 10 min.
Quality control was performed by RP-HPLC. The
radiofolates were prepared by dilution with 0.9% NaCl
(saline) with 0.1% bovine serum albumin (BSA). For the
saturation binding studies 67/natGa-P3026 and 67/natGa-
P1254, with tracer amounts of 67Ga, were used to afford
structurally characterized homogeneous compounds.
Cell cultures
The KB and HT1080 cell lines were obtained from
American Type Culture Collection (ATCC, Manassas, VA,
USA) (CCL-17 and CCL-21, respectively). The cells were
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cultured as monolayers at 37°C/5% CO2 in folate-free
RPMI 1640 medium (KB) and DMEM high-glucose (4.5 g/l)
medium (HT1080). The media were supplemented with 10%
fetal calf serum (FCS), L-glutamine and antibiotics (penicillin,
100 IU/ml; streptomycin, 100 μg/ml).
For the in vitro experiments the KB cells were seeded
into 6-well plates (0.8–1×106 cells/well) and incubated at
37°C/5% CO2 overnight. On the day of the experiment the
medium was removed, the cells were washed with RPMI
medium without FCS and antibiotics and 800 μl/well pure
medium were added. The plates were incubated at 37°C/5%
CO2 for 1 h. All experiments were performed in triplicate.
For the in vivo experiments the cells were washed and
suspended in sterile phosphate-buffered saline (PBS) at a
concentration of 1×107 cells/ml.
Radiofolate cell uptake and internalization studies
For the internalization experiments 2.5 pmol/100 μl per
well of each radiofolate was added and the cells were
incubated at 37°C/5% CO2 for preselected time points of
30 min, 1, 2 and 4 h at a final concentration of 2.5 nM. A
1,000-fold excess of folic acid (FA) was used to determine
nonspecific binding and internalization. At the preselected
time points the medium was removed, the cells were
washed 2×1 ml PBS and were treated twice for 5 min with
1 ml ice-cold glycine solution (0.05 mol/l, pH 2.8) to
distinguish between cell surface-bound (acid releasable)
and internalized (acid resistant) radiofolate. Finally, the
cells were detached by treatment with 1 ml of NaOH 1 N,
followed by two washes. The radioactivity of all fractions
was measured in the gamma counter. Receptor-specific
internalization was calculated by subtracting the value
found for blocked uptake from the total uptake and
expressed as percentage of the applied radioactivity.
Externalization studies
The kinetics of externalization was studied after the cells
were incubated for 2 h with 2.5 pmol/well. The medium
was then removed and the cells were washed with 2×1 ml
PBS and then exposed to an acid wash with glycine buffer,
as described above, to dissociate cell surface-bound radio-
folate. Pure medium (1 ml/well) was added and the cells
were then incubated at 37°C. At different time points (15,
30, 60, 90, 120 and 240 min) the external medium was
removed (followed by two washes with PBS) for quantifi-
cation in a gamma counter and replaced with fresh 37°C
medium. Finally, the cells were removed with NaOH 1 N
and quantified in a gamma counter. The recycled fraction
Folate conjugates Chemical structure 
P3026 
C37H51N13O12 
M.W. 869.90
HN
N N
N
N
H
N
H
H
N
H2N
O
HO O
O
O
NH
N
N
N
N
OH
O
O
OHHO
O
O
P1254 
C45H67N13O15 
M.W. 1030.11
HN
N N
N
N
H
N
H
H
N O O O
H2N
O
HO O
H
N
O
O
N
N
N
N
OH
O
O
OHHO
O
O
P3139 
C35H46N12O14 
M.W. 858.83 HN
N N
N
N
H
N
H
H
N
H2N
O
HO O
O
O
N
H
N
O
N
N
OH
O
OH
O
OH
O
O OH
Fig. 1 Structures of the new DOTA-folate conjugates (P1254 and P3026) and of the reference molecule DTPA-folate (P3139)
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was expressed as the percentage of the total internalized
amount.
Saturation binding assays
Increasing concentrations of 67/natGa-P1254 and 67/natGa-
P3026, ranging from 0.1 to 1,000 nmol/l, were used
for saturation binding experiments on intact cells. FA at a
concentration of 1 mM was used to quantify the
nonspecific binding. The cells were incubated for 2 h at
4°C in the presence of the radiofolates at different
concentrations. The medium was removed and the cells
were washed with 2×1 ml PBS; this represented the free
fraction. The cells were collected with NaOH 1 N, which
corresponded to the bound fraction. The radioactivity of
both fractions was measured in a gamma counter.
Dissociation constant (Kd) and maximum number of
binding sites (Bmax) values were calculated from the
analysis of the data using GraphPad Prism 5.01 software
(GraphPad Software Inc.).
Tumour model and animal biodistribution studies
All animal studies were performed in accordance with Swiss
regulations (approval 789). Athymic female nude mice
(4–5 weeks old, 18–20 g) were subcutaneously inoculated in
the right front leg with 1×106 KB cells and in the other leg
with 1×106 HT1080 cells. Tumours were allowed to grow for
9–10 days, when tumours were 68.6±22.7 mg and 99.8±
56.2 mg for KB and HT1080, respectively. The animals
stayed on a folate-deficient diet (semisynthetic product with
50 μg/kg of folate, S.A.F.E., Épinay-sur-Orge, France) 1 week
before the implantation of the tumours until the end of the
studies.
For the biodistribution studies the mice were divided into
groups of between four and seven and injected with 0.4 nmol/
1.5 MBq per 100 μl of each radiofolate into the tail vein.
Nonspecific uptake in tumour and FR-positive organs was
determined by 5 min pre-injection of 40 nmol FA/100 μl. At
preselected time points of 20 min, 1, 2, 4 and 24 h post-
injection (p.i.) the mice were sacrificed. The organs of interest
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were collected, blotted dry, weighed and counted in a gamma
counter. The results are expressed as the percentage of injected
dose per gram (%ID/g ± SD) for each organ.
PET/CT images
For the PET/CT images the mice were injected intravenously
with 0.4 nmol/4 MBq per 100 μl of 68Ga-P3026. One hour
later the mice were sacrificed, the kidneys were removed
surgically and the mice were then scanned for 30 min using a
routine combined PET/CT scanner (Discovery STE, GE
Medical Systems, Waukesha, WI, USA). Images of mice
pre-injected with FA, as described above, were also acquired.
A scout scan (180°, 10 mA, 120 kV) was done to establish a
protocol for all other scans. CT scans were acquired with
minimum slice distance and the highest possible tube current
for these settings (320 mA @ 120 keV). PET emission events
were collected in 3-D scanning mode (septa out) over 30 min,
starting immediately after the CT scan. They were corrected
for decay of 68Ga and random events and reconstructed using
the manufacturer’s 3-D ordered subset expectation maximiza-
tion (OSEM) algorithm to 47 slices [display field of view
(FOV)=6.4 cm, 128×128 matrix, resulting pixel size=
0.5 mm], once for each mouse separately in the centre of
the reconstruction cylinder.
Statistical analysis
Student’s t test was used to determine statistical signifi-
cance. Differences at the 95% confidence level (p<0.05)
were considered significant.
Results
Synthesis and radiolabelling
The synthetic strategy followed preserved the natural S
configuration of the asymmetric carbon of the folate moiety
and resulted selectively in the formation of the γ
regioisomers. The overall yield of synthesis was∼10%.
All conjugates were obtained in 92–95% purity, as
confirmed by RP-HPLC. The observed mass in ESI-MS
was: 893.2 [M+Na]+ for P3026, 1,068.9 [M+K]+ for P1254
and 859.7 [M+H]+ for P3139. The radiofolates were
prepared in a labelling yield of>95%. Specific activity of
the 67Ga- and 68Ga-DOTA-folate conjugates was at the
level of 7 and 10 MBq/nmol, respectively.
Cell uptake, internalization and externalization studies
All radiofolates are highly and rapidly associated with the
KB cells within the initial 30 min of incubation. Figure 3
shows the cell uptake and retention of the radiofolates into
KB cells over time. Continued exposure of the cells to the
radiofolates resulted in a slight increase of uptake from
30 min to 4 h, which was more obvious in the case of 67Ga-
P3026. 67Ga-P3026 was found to have the highest cell-
associated uptake (80%) and the highest cell surface
binding value (63.9±1.2%), compared to 67Ga-P1254 and
111In-P3139 (55.7±1.5% and 49.6±2.5%, respectively), at
4 h. The internalized fraction increased with time, from
30 min to 4 h. The highest value was found for 67Ga-P3026
(16.5±0.4%), while for the other radiofolates this value
ranged from 9.5 to 12%. Blocking experiments performed
with excess of FA showed negligible nonspecific binding
on the cell surface, while less than 0.5% of total added
radioactivity was found to be internalized (data not shown).
These results demonstrate the high specificity of the folate
conjugates for the FRs in vitro. As far as the externalization
concerns, 67Ga-P1254 showed the highest retention in the
cells (82% retained in the cells after 4 h at 37°C).
Comparable values were found for 67Ga-P3026, while for
111In-P3139 up to 40% was found to be released from the
cells into the medium.
Saturation binding studies
Saturation binding studies were performed at 4°C, in order
to allow binding of the radiofolates to the receptor but to
avoid endocytosis. The results are presented in Fig. 4. Both
67/natGa-DOTA-folates exhibited the same affinity for the
FR, with Kd values of 4.65±0.82 nM for
67/natGa-P3026
and 4.27±0.42 nM for 67/natGa-P1254. The Bmax values
were also at the same level for both conjugates (10.65±0.45
nM for 67/natGa-P3026 and 11.44±0.27 nM for 67/natGa-
P1254). A number of approximately 6.4 to 6.9×106
molecules of 67/natGa-DOTA-folates was estimated to be
associated with each KB cell when maximum binding was
achieved.
Biodistribution studies
Biodistribution studies of all radiofolates were performed in
a dual tumour model of nude mice bearing FR-positive KB
tumours and FR-negative HT1080 tumours from 20 min up
to 24 h p.i. The biodistribution profile of all radiofolates is
characterized by efficient clearance from the blood, high
and specific receptor-mediated tumour uptake and high
radioactivity accumulation in the kidneys. The results are
summarized in Tables 1, 2 and 3.
The uptake in the FR-positive tumour was found to be
high from the earliest time point of the study (20 min p.i.),
having similar maximum values for all conjugates at 4 h p.i.
(67/68Ga-P3026: 14.29±4.14%ID/g, 67/68Ga-P1254: 13.10±
0.65%ID/g and 111In-P3139: 12.13±2.16%ID/g). However,
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the difference in the tumour uptake was not significant from
1 to 4 h p.i. (p>0.05). A slow washout from the tumour
occurred, as the values were still high 24 h p.i. As was
expected kidneys accumulated high amounts of radioactivity
and as a consequence tumour to kidney ratios were low at all
investigated time points. In all cases, the radioactivity
concentration in the FR-negative HT1080 tumours was much
lower, around 1–2%ID/g. The specificity of the conjugates for
the FR was also confirmed by blocking experiments in which
tumour and kidney uptake were drastically reduced when FA
was pre-injected.
Focusing on the tumour to non-tumour ratios, all values
were already high at 1 h p.i. (tumour to blood: ∼40, tumour
to liver: ∼2.5, tumour to muscles: 5–10) and increased with
time. This was not the case for the tumour to kidney ratios
which were low and remained essentially the same from
20 min up to 4 h p.i. Among the conjugates 111In-P3139
seemed to have a slightly better tumour to kidney ratio but
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expressed as the percentage that remained in the cells from the total
amount internalized (100%). All data are from three independent
experiments with triplicates in each experiment
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Table 1 Biodistribution results (%ID/g ± SD, n=4–7) and tumour to non-tumour ratios of 67/68Ga-P3026 in nude mice bearing KB and HT1080
tumours
Organ 20 min 1 h 2 h 4 h 4 h blocking 24 h
Blood 0.94±0.25 0.32±0.03 0.21±0.01 0.20±0.04 0.09±0.02 0.08±0.01
Heart 3.74±0.39 3.24±0.23 2.99±0.26 2.54±0.21 0.06±0.01 2.55±0.29
Liver 7.62±1.75 4.88±0.81 2.92±0.48 2.08±0.08 0.14±0.04 2.28±0.22
Spleen 0.59±0.09 0.60±0.07 0.55±0.16 0.60±0.22 0.08±0.01 0.44±0.06
Lung 2.35±0.74 1.99±0.21 1.73±0.33 1.47±0.27 0.11±0.02 1.10±0.23
Kidney 62.90±11.57 82.21±5.53 87.78±12.37 103.01±24.58 6.36±1.13 95.67±11.37
Stomach 2.66±0.56 2.12±0.14 1.95±0.11 1.66±0.18 0.08±0.02 1.60±0.21
Intestine 0.92±0.13 0.65±0.19 0.68±0.13 0.82±0.18 0.09±0.02 0.77±0.20
Adrenal 5.77±0.74 4.63±0.95 3.79±0.57 3.21±0.40 0.13±0.05 2.54±0.68
Pancreas 4.85±0.28 4.69±0.16 3.86±0.55 3.26±0.43 0.07±0.02 2.67±0.33
Pituitary 1.73±0.24 3.57±0.55 2.09±0.78 2.32±0.42 0.11±0.01 1.79±0.16
Muscle 2.12±0.57 2.19±0.21 2.25±0.43 1.70±0.32 0.03±0.01 1.28±0.08
Bone 0.53±0.21 0.47±0.14 0.44±0.09 0.37±0.13 0.08±0.02 0.51±0.05
KB tumour 8.82±1.59 11.77±2.76 10.64±2.13 14.29±4.14 2.39±0.71 7.36±1.37
HT1080 tumour 1.78±0.76 1.16±0.65 1.48±0.91 1.04±0.52 0.09±0.02 0.48±0.05
Tumour to non-tumour ratios
Tumour to blood 9.91±3.18 36.19±5.05 50.12±11.21 70.01±7.37 90.11±18.18
Tumour to liver 1.12±0.35 2.62±0.72 4.07±1.30 6.88±2.08 3.27±0.75
Tumour to muscles 4.40±1.37 5.39±1.20 4.84±1.21 8.87±3.78 5.73±0.91
Tumour to kidneys 0.14±0.03 0.14±0.04 0.12±0.02 0.12±0.01 0.08±0.01
Table 2 Biodistribution results (%ID/g ± SD, n=4–7) and tumour to non-tumour ratios of 67/68Ga-P1254 in nude mice bearing KB and HT1080
tumours
Organ 20 min 1 h 2 h 4 h 4 h blocking 24 h
Blood 0.84±0.12 0.32±0.02 0.26±0.03 0.21±0.01 0.12±0.01 0.07±0.01
Heart 2.04±0.24 1.96±0.14 1.90±0.22 1.94±0.15 0.06±0.01 1.67±0.22
Liver 8.80±1.08 5.48±1.13 3.68±0.95 2.24±0.17 0.20±0.02 2.40±0.82
Spleen 0.58±0.19 0.45±0.09 0.54±0.12 0.46±0.06 0.11±0.01 0.35±0.06
Lung 1.86±0.50 1.30±0.22 1.40±0.27 1.30±0.20 0.18±0.03 0.89±0.11
Kidney 79.32±14.08 84.85±13.69 98.43±15.40 103.95±16.96 3.48±0.70 93.95±11.13
Stomach 1.82±0.11 1.45±0.15 1.54±0.19 1.60±0.13 0.09±0.01 1.12±0.19
Intestine 0.69±0.09 0.54±0.08 0.49±0.09 0.62±0.05 0.14±0.02 0.73±0.19
Adrenal 6.54±1.06 4.05±1.04 4.37±0.81 2.99±0.30 0.16±0.05 2.26±0.60
Pancreas 3.14±0.16 2.75±0.32 2.68±0.37 2.80±0.28 0.06±0.01 2.25±0.39
Pituitary 2.02±0.37 2.47±0.17 2.30±0.57 1.65±0.85 0.07±0.04 0.73±0.30
Muscle 1.43±0.13 1.37±0.46 1.32±0.21 1.44±0.33 0.03±0.01 1.07±0.02
Bone 0.64±0.35 0.25±0.04 0.20±0.07 0.26±0.04 0.09±0.01 0.28±0.05
KB tumour 8.87±1.06 12.51±1.54 10.37±0.36 13.10±0.65 0.81±0.17 7.41±1.49
HT1080 tumour 1.39±0.87 1.43±0.91 2.36±0.15 1.26±0.53 0.09±0.01 1.49±0.75
Tumour to non-tumour ratios
Tumour to blood 10.73±1.67 39.27±2.35 40.80±2.07 63.00±2.75 102.34±19.04
Tumour to liver 1.03±0.23 2.35±0.53 2.91±0.78 5.89±0.66 3.23±0.72
Tumour to muscles 6.27±1.21 9.57±1.70 8.48±1.25 9.37±1.55 6.94±1.34
Tumour to kidneys 0.11±0.02 0.15±0.01 0.11±0.02 0.13±0.03 0.08±0.01
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it was found to be statistically not significant, compared to
67/68Ga-DOTA-folates (p>0.05).
PET/CT images
PET/CT images were performed with 68Ga-P3026 at 1 h p.i.
For this study the kidneys were surgically removed from
the mice before imaging, in order to localize the tumour,
since kidneys accumulate high amounts of radioactivity.
The PET/CT images (Fig. 5) clearly showed high and
specific uptake of 68Ga-P3026 in the FR-positive tumour
and negligible uptake in the FR-negative tumour, with very
good tumour to non-tumour contrast. The PET/CT images
of mice pre-injected with FA, where kidneys had not been
removed, confirmed the specificity of the radiofolate for the
FR. High uptake was also observed in the salivary glands,
which was negligible in the case of FA pre-injection,
demonstrating the receptor-mediated uptake of the
radiofolate by this tissue.
Discussion
Ovarian cancer at its early stages is difficult to diagnose
until it spreads and advances to later stages. Since
metastatic spreading is a negative prognostic factor for
survival there is an acute need for a diagnostic tool
allowing early detection. The folate receptor can be used
as a tumour-associated molecular target in this case since it
is highly expressed in ovarian and endometrial carcinomas.
On the other hand, a rational design and development of a
selective and specific PET radiotracer for this target gives
the chance of using the advantages of PET/CT technology
for early detection, staging and follow-up of patients
suffering from ovarian cancer. Moreover, it will provide
information on the presence or absence of the molecular
target, which is extremely important for the design and
implementation of therapeutic approaches.
Based on the above rationale we designed and developed
PET folate-based radiotracers, using the generator-produced
68Ga, which would make the preparation of the radiophar-
maceutical possible in every hospital. We chose DOTA as a
chelator and conjugated it to folic acid using different
spacer molecules as potential pharmacokinetic modifiers,
such as 1,2-diaminoethane and 3-{2-[2-(3-amino-propoxy)-
ethoxy]-ethoxy}-propylamine, resulting in the conjugates
P3026 and P1254, respectively. Folic acid has two
carboxylic acid groups (α and γ) available for coupling.
It is still unclear whether a free α carboxyl group is
necessary for folate conjugates to retain binding to the FR.
As there is some debate on the affinity of the α
regioisomer, while the γ regioisomer is known to have
high affinity for the FR [19, 33, 34], we followed the
synthetic strategy described in the “Materials and methods”
Table 3 Biodistribution results (%ID/g ± SD, n=4–7) and tumour to non-tumour ratios of 111In-P3139 in nude mice bearing KB and HT1080
tumours
Organ 20 min 1 h 2 h 4 h 4 h blocking 24 h
Blood 0.81±0.19 0.24±0.02 0.17±0.04 0.10±0.02 0.01±0.00 0.08±0.02
Heart 4.62±0.63 4.32±0.76 3.65±0.37 3.08±0.26 0.01±0.01 2.24±0.55
Liver 7.49±1.11 4.19±1.71 2.29±0.70 1.52±0.23 0.04±0.01 0.98±0.24
Spleen 0.72±0.14 0.62±0.15 0.57±0.08 0.61±0.14 0.04±0.01 0.63±0.21
Lung 2.28±0.20 1.86±0.17 1.97±0.30 1.77±0.31 0.05±0.01 1.46±0.32
Kidney 55.97±7.99 67.32±11.07 68.78±6.72 77.09±10.67 2.97±0.43 72.81±15.61
Stomach 2.34±0.33 1.95±0.31 1.94±0.33 2.04±0.33 0.04±0.01 1.38±0.27
Intestine 1.06±0.43 0.87±0.11 0.80±0.10 0.61±0.19 0.03±0.01 0.56±0.06
Adrenal 4.93±1.13 3.77±0.91 3.03±0.50 3.24±0.46 0.08±0.03 2.30±0.38
Pancreas 4.77±0.76 3.42±0.43 4.00±0.94 3.46±0.54 0.02±0.01 2.47±0.34
Pituitary 3.55±0.84 3.91±0.20 3.54±0.87 3.25±0.61 0.03±0.02 3.36±0.50
Muscle 2.41±0.09 2.40±0.48 2.16±0.34 1.80±0.22 0.01±0.01 1.36±0.03
Bone 0.61±0.04 0.42±0.13 0.46±0.12 0.56±0.23 0.04±0.02 0.56±0.22
KB tumour 9.66±1.09 11.11±1.51 12.46±0.77 12.13±2.16 0.61±0.21 10.64±3.67
HT1080 tumour 1.80±0.55 2.01±0.83 0.91±0.57 0.86±0.45 0.04±0.01 0.62±0.18
Tumour to non-tumour ratios
Tumour to blood 12.34±2.51 46.11±8.54 76.30±16.53 118.07±22.28 131.76±30.70
Tumour to liver 1.30±0.17 2.98±1.18 5.76±1.45 8.19±2.13 11.77±5.92
Tumour to muscles 4.01±0.43 4.70±0.67 5.84±0.73 6.91±2.14 7.79±2.58
Tumour to kidneys 0.17±0.03 0.17±0.01 0.18±0.02 0.16±0.01 0.12±0.01
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section to obtain the selective γ regioisomers of our
conjugates. The DOTA-folate conjugates were labelled
with 67Ga (T1/2=3.26 days), which gives the possibility of
investigations at late time points. The 67/68Ga-DOTA-
folates were preclinically evaluated along with the 111In-
DTPA-folate (111In-P3139), which was used as a reference
molecule [19, 20, 22, 35].
All of the conjugates exhibit a rapid FR association in
vitro, with the 67/68Ga-P3026 and 67/68Ga-P1254 showing
higher cell surface binding activity and internalization rate,
compared to 111In-P3139. It is worth mentioning that 67/68Ga-
P3026 showed the highest cell-associated uptake, reaching
80% of the total added activity, at 4 h, compared to 60%
found for 111In-P3139 under the same experimental conditions
and also to 40–60% published for different radiofolates and
cell lines, including KB cells [16, 30, 36]. A twofold higher
cellular retention was observed for the 67/68Ga-P3026 and
67/68Ga-P1254, compared to 111In-P3139. The retention of the
radiofolates in the cells may be an important parameter for
potential use of these conjugates in therapeutic applications, as
cellular retention determines the radiation dose deposited in
the tumour [37].
67/68Ga-P3026 and 67/68Ga-P1254 exhibited high affinity
for the FR with Kd values in the low nanomolar range,
comparable to folic acid [1, 16, 30], while the maximum
number of molecules associated per KB cell is in agreement
with the literature [14, 26, 36].
The two new 67/68Ga-DOTA-folates target selectively
FR-expressing tumours in vivo, with very high tumour to
non-tumour contrast, except the kidneys where filtration of
folates and reabsorption from the primary urine via the FR in
proximal tubules leads to high retention of radioactivity. To
our knowledge, there is only one folate conjugate (DF-folate)
which has been studied with 66/67/68Ga and PET images have
been acquired with 66Ga [29], while no 68Ga has been used
for PET imaging with folate derivatives. Despite the good
pharmacokinetics of the 66/67Ga-DF-folate conjugate and its
primary excretion via urine, > 20% is cleared via intestines
4 h p.i. [27, 28] which is a drawback since radioactivity will
interfere with imaging of abdominal tumours, such as ovarian
carcinoma. The 67/68Ga-DOTA-folates showed better pharma-
cokinetics compared to 66/67Ga-DF-folate with efficient
clearance from the blood, elimination via the kidneys and
high and specific receptor-mediated tumour uptake, while no
significant amount of radioactivity is concentrated in the
gastrointestinal track.
The biodistribution profile of the 67/68Ga-DOTA-folates
is similar to the reference molecule 111In-P3139 in a side-
by-side comparison, as it is known that parameters such as
tumour size, serum folate concentration, folate conjugate
structure and administered dose can affect the in vivo
results [20, 28, 35, 38]. Among 67/68Ga-P3026, 67/68Ga-
P1254 and 111In-P3139, tumour uptake, kidney uptake and
also tumour to kidney ratio, at 1 and 4 h p.i., were at the
same level, with differences statistically not significant
(p>0.05). This shows that the replacement of DTPA by
DOTA (P3139 vs P3026), but also the replacement of the
spacer (P1254 vs P3026), did not alter the biodistribution
profile. However, this was not the case when the chelator
DF was replaced by DTPA (DF-folate vs P3139). The
difference in the in vivo behaviour of 67Ga-DF-folate,
compared to 111In-P3139, 67/68Ga-P3026 and 67/68Ga-
P1254, is possibly due to the dissociation of the metal,
rather than the chelator and/or the spacer used, as there are
indications that in nanomolar concentrations the stability of
the Ga-DF complex may be reduced [39].
KB tumor
a 
HT1080 tumor 
b
Fig. 5 PET/CT images 1 h p.i. of
68Ga-P3026 (a), where specific
uptake in the KB tumour (FR+),
but also in the salivary glands,
was observed, while no uptake in
the HT1080 tumour (FR-) was
observed. In this mouse the
kidneys were removed prior to
imaging due to the high kidney
uptake of the folate derivatives. b
68Ga-P3026 co-injected with
folic acid (100-fold excess)
demonstrated the specific uptake
of the radiotracer, since reduced
kidney uptake and negligible
tumour uptake in the FR+tumour
was observed
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The clear visualization of the FR-positive tumours with
PET/CT images of 68Ga-P3026 proved the potency of these
radiotracers to localize and detect tumours expressing the
FR. We used a somewhat unusual way to eliminate the
intensive signal received from the kidneys, by removing
the kidneys surgically. Müller et al. have introduced the use
of the antifolate pemetrexed for the elimination of the
radiofolates concentrated in the kidneys [35]. It has also
been shown that manipulation of the radiofolate uptake in
the kidney, tumour and normal tissues, as well as in tumour
to non-target contrast, can be achieved with co-administration
of modest doses of folic acid [20, 28]. However, for the
purpose of our study, no effort was made for such an
optimization. Except the high and specific tumour uptake,
confirmed by blocking experiments, PET/CT images
demonstrated also high uptake in the salivary glands. The
specific uptake of radiofolates in this tissue has recently been
demonstrated with SPECT/CT imaging [17], while in the
past no evidence of such an uptake was available. In
addition, one should not forget that in the animal model
the mice are on a folate-deficient diet. Interestingly, when we
injected the radiofolates into non-tumour-bearing mice,
without being on a folate-deficient diet, no uptake was
found in the salivary glands on PET/CT images where only
kidneys were visualized 1 h p.i. (data not shown). Obviously,
this finding needs further investigation, as we do not really
know how it reflects the human situation. Moreover, such an
uptake has not been found in patients studied with radio-
folates [22, 23].
The new 67/68Ga-DOTA-folate conjugates showed better
pharmacokinetics, compared to 66/67/68Ga-DF-folate and
similar to the clinically evaluated 111In-DTPA-folate.
111In-DTPA-folate scintigraphy in phase I/II clinical trials
for imaging ovarian cancer showed that differentiation
between benign and malignant masses was possible in
patients with suspected new disease [22]. No significant
uptake in any organ except kidney and tumour was
observed and good contrast was achieved within 1 h
suggesting that short-lived radionuclides, such as 68Ga,
can be exploited for imaging applications [22, 40].
Additionally, 99mTc-EC20 scintigraphy in patients with
different solid tumours allowed FRs to be identified in
recurrent or metastatic disease [23, 40]. In these clinical
applications both radiofolates were shown to be safe.
Single-dose intravenous injection was well tolerated in
humans; no serious adverse reactions or changes in vital
signs have been reported. Accordingly, in our preclinical
evaluation no pharmacological side effects were observed
in any group of animals.
At the beginning of our study no published data on
DOTA-folate conjugates were available. Meanwhile two
groups have presented their data based on similar
conjugates in the concept of a therapeutic approach, either
by using radionuclides such as 177Lu [38] or by investigat-
ing natGa(III) compounds as anticancer agents [33], while
DOTA conjugated to a monoclonal antibody has also been
used for radioimmunotargeting of FR [41]. Their and our
encouraging results make us believe that the development
of these DOTA-folate conjugates has a positive impact on
the folate receptor-targeted imaging and/or therapy. The
high kidney uptake is a major concern, but for diagnostics it
is not such a serious drawback as in the case of therapeutic
radiopharmaceuticals, especially when PET isotopes with a
short half-life are used. Moreover, preclinical studies for
modulation of kidney radiotracer uptake with antifolates are
ongoing [35, 38]. We also consider the use of 68Ga
preferable to 66Ga for PET imaging, as far as dosimetry
and availability are concerned.
In summary, two new DOTA-folate conjugates were
developed and efficiently labelled with 68Ga in labelling
yields and specific activities which allow clinical application.
High and selective targeting of FR along with good tumour
to background ratio at early time points after injection can be
achieved, showing the potentiality of these compounds as
PET radiotracers for FR-positive tumours. The character-
istics of the 67/68Ga-DOTA-folate conjugates are comparable
to 111In-DTPA-folate, which has already been used in
clinical trials. This new development gives an option to
improve the existing strategies of detection and treatment of
FR-positive tumours, such as ovarian carcinoma.
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